The Valeda LDS treatment for dry AMD is now FDA approved
LumiThera has received U.S. FDA authorisation to market its Valeda® Light Delivery System, the first FDA-approved treatment for vision loss due to dry age-related macular degeneration (AMD). The non-invasive photobiomodulation (PBM) device demonstrated improved visual acuity and safety over 24 months in the pivotal LIGHTSITE III trial, with results showing that Valeda slowed disease progression and preserved retinal health compared to untreated patients. The FDA’s De Novo authorization establishes a new treatment category for PBM in dry AMD.
LumiThera’s Valeda system uses targeted light therapy to enhance visual function in patients with dry AMD, which is the leading cause of central vision loss among those over 55. Approved through the FDA’s De Novo pathway, this system sets a new standard for PBM treatments, showing promise in preventing AMD-related vision decline in early stages.
At John Rose Eye Care in Kingston Upon Thames we have been offering the Valeda LDS treatment for dry AMD since 2019 and have been successfully treating clients since.
for more information click this link https://lumithera.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd-patients-to-improve-vision-2/
